Inventor · disambiguated record
Maria Amann
Also filed as: AMANN MARIA
14 granted patents·18 pending applications·133 citations·filing 2011–2025
91Inventor score
Top patents by PatentIndex Score
32 records- 0197US11306154B2Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Apr 19, 2022·13 cites·56 claims
- 0297US11267903B2Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Mar 8, 2022·17 cites·46 claims
- 0397US10464981B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Nov 5, 2019·33 cites·22 claims
- 0496US10392445B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Aug 27, 2019·31 cites·39 claims
- 0595US11149083B2Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moietyHOFFMANN—LA ROCHE INC·Filed 2018·Granted Oct 19, 2021·12 cites·25 claims
- 0695US10526413B2Bispecific antibodies specific for OX40HOFFMANN LA ROCHE·Filed 2016·Granted Jan 7, 2020·23 cites·20 claims
- 0787US2025101135A1Antigen binding molecules comprising a tnf family ligand trimerHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 0882US11780919B2Bispecific antigen binding molecules targeting OX40 and FAPHOFFMANN LA ROCHE·Filed 2021·Granted Oct 10, 2023·1 cites·24 claims
- 0980US12441812B2Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding moleculesHOFFMANN LA ROCHE·Filed 2022·Granted Oct 14, 2025·0 cites·28 claims
- 1075US12202870B2Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereofHOFFMANN LA ROCHE·Filed 2021·Granted Jan 21, 2025·0 cites·40 claims
- 1175US11639394B2Bispecific antigen binding molecule for a costimulatory TNF receptorHOFFMANN LA ROCHE·Filed 2019·Granted May 2, 2023·1 cites·9 claims
- 1274US11453722B2Bispecific antigen binding molecule for a costimulatory TNF receptorHOFFMANN LA ROCHE·Filed 2019·Granted Sep 27, 2022·1 cites·13 claims
- 1373US12227594B2Bispecific 2+1 contorsbodiesHOFFMANN LA ROCHE·Filed 2018·Granted Feb 18, 2025·1 cites·14 claims
- 1473US2024117049A1Bispecific antigen binding molecules targeting ox40 and fapHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1570US12240911B2Bispecific antibodies specific for OX40HOFFMANN LA ROCHE·Filed 2019·Granted Mar 4, 2025·0 cites·20 claims
- 1670US2023227584A1Bispecific antibodies comprising a modified c-terminal crossfab fragmentHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1768US2022073646A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1866US2023123178A1Antigen Binding Molecules comprising a TNF family ligand trimer and PD1 binding moietyHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1966US2020270321A1Antigen binding molecules comprising a trimeric tnf family ligandHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2062US2025352822A1Combinations and uses thereofHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 2161US2024043535A1IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULESHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2261US2025257141A1Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonistHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2361US2021009656A1C-terminally fused tnf family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2460US2019194291A1C-terminally fused tnf family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 2557US2019211113A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 2655US2019185566A1Antigen Binding Molecules comprising a TNF family ligand trimer and PD1 binding moietyHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 2755US2024352136A1Antibodies for the treatment of amlHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2851US2017247467A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 2948US2019016771A1Trimeric costimulatory tnf family ligand-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 3048US2020392237A1Combination therapy with targeted OX40 agonistsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3142US11536716B2Cell based assay for determining antibody or ligand binding and functionHOFFMANN LA ROCHE·Filed 2016·Granted Dec 27, 2022·0 cites·26 claims
- 3236US2014242081A1Dosing regimens for treatment of cea-expressing cancersHAMMOND SCOTT·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Maria Amann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →